Toppgene analysis for Wikipedia protein communities, toppgene analysis, cc57_7, positive side

Go To Start Page
Input Parameters [Show Detail]
Training Results [Expand All] [Download All] [Sparse Matrix]
Display pValues and Scores as Table row limit

1: GO: Molecular Function [Display Chart] 7 input genes in category / 14 annotations before applied cutoff / 18661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0015485 cholesterol binding 1.081E-4 9.446E-4 3.071E-3 1.514E-3 2 43
2 GO:0032934 sterol binding 1.349E-4 9.446E-4 3.071E-3 1.889E-3 2 48
3 GO:0005496 steroid binding 6.223E-4 2.573E-3 8.366E-3 8.712E-3 2 103
4 GO:0043178 alcohol binding 7.351E-4 2.573E-3 8.366E-3 1.029E-2 2 112
5 GO:0032052 bile acid binding 3.372E-3 9.153E-3 2.976E-2 4.720E-2 1 9
6 GO:0017166 vinculin binding 4.493E-3 9.153E-3 2.976E-2
6.291E-2
 1 12
7 GO:0005096 GTPase activator activity 4.577E-3 9.153E-3 2.976E-2
6.407E-2
 2 283
8 GO:0030695 GTPase regulator activity 5.536E-3 9.687E-3 3.150E-2
7.750E-2
 2 312
9 GO:0060589 nucleoside-triphosphatase regulator activity 6.693E-3 1.041E-2 3.385E-2
9.370E-2
 2 344
10 GO:0043274 phospholipase binding 8.225E-3 1.151E-2 3.744E-2
1.151E-1
 1 22
11 GO:0042169 SH2 domain binding 1.269E-2 1.615E-2
5.250E-2
1.776E-1
 1 34
12 GO:0033293 monocarboxylic acid binding 2.926E-2 3.414E-2
1.110E-1
4.097E-1
 1 79
Show 7 more annotations

2: GO: Biological Process [Display Chart] 7 input genes in category / 209 annotations before applied cutoff / 18623 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0006869 lipid transport 1.734E-4 2.453E-2
1.453E-1
 3.624E-2 3 324
2 GO:0010876 lipid localization 2.347E-4 2.453E-2
1.453E-1
 4.906E-2 3 359

3: GO: Cellular Component [Display Chart] 7 input genes in category / 31 annotations before applied cutoff / 19061 genes in category

No results to display

4: Human Phenotype [Display Chart] 2 input genes in category / 205 annotations before applied cutoff / 4707 genes in category

No results to display

5: Mouse Phenotype [Display Chart] 7 input genes in category / 329 annotations before applied cutoff / 10355 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 MP:0004773 abnormal bile composition 6.662E-5 2.192E-2
1.397E-1
 2.192E-2 2 19
2 MP:0005085 abnormal gallbladder physiology 2.580E-4 4.244E-2
2.705E-1
8.487E-2
 2 37

6: Domain [Display Chart] 7 input genes in category / 26 annotations before applied cutoff / 18735 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 SM00234 START SMART 2.001E-19 3.793E-18 1.462E-17 5.202E-18 6 13
2 PS50848 START PROSITE 5.836E-19 3.793E-18 1.462E-17 1.517E-17 6 15
3 PF01852 START Pfam 5.836E-19 3.793E-18 1.462E-17 1.517E-17 6 15
4 IPR002913 START lipid-bd dom InterPro 5.836E-19 3.793E-18 1.462E-17 1.517E-17 6 15
5 IPR023393 START-like dom InterPro 1.177E-17 5.098E-17 1.965E-16 3.059E-16 6 23
6 3.30.530.20 - Gene3D 1.177E-17 5.098E-17 1.965E-16 3.059E-16 6 23
7 IPR000799 StAR-like InterPro 7.177E-7 2.666E-6 1.028E-5 1.866E-5 2 4
8 PF07647 SAM 2 Pfam 1.073E-4 3.486E-4 1.344E-3 2.789E-3 2 43
9 SM00324 RhoGAP SMART 2.239E-4 4.772E-4 1.839E-3 5.821E-3 2 62
10 PF00620 RhoGAP Pfam 2.312E-4 4.772E-4 1.839E-3 6.011E-3 2 63
11 1.10.555.10 - Gene3D 2.386E-4 4.772E-4 1.839E-3 6.203E-3 2 64
12 PS50238 RHOGAP PROSITE 2.386E-4 4.772E-4 1.839E-3 6.203E-3 2 64
13 IPR000198 RhoGAP dom InterPro 2.386E-4 4.772E-4 1.839E-3 6.203E-3 2 64
14 IPR029868 StARD5 InterPro 3.736E-4 6.476E-4 2.496E-3 9.714E-3 1 1
15 IPR028854 DLC1 InterPro 3.736E-4 6.476E-4 2.496E-3 9.714E-3 1 1
16 IPR008936 Rho GTPase activation prot InterPro 4.511E-4 7.331E-4 2.826E-3 1.173E-2 2 88
17 PS50105 SAM DOMAIN PROSITE 5.255E-4 7.913E-4 3.050E-3 1.366E-2 2 95
18 IPR001660 SAM InterPro 5.478E-4 7.913E-4 3.050E-3 1.424E-2 2 97
19 IPR015789 Twist-related InterPro 7.471E-4 1.022E-3 3.941E-3 1.943E-2 1 2
20 IPR013761 SAM/pointed InterPro 7.956E-4 1.034E-3 3.986E-3 2.069E-2 2 117
21 SM00454 SAM SMART 3.243E-2 4.015E-2
1.547E-1
8.431E-1
 1 88
22 4.10.280.10 - Gene3D 4.003E-2 4.363E-2
1.682E-1
1.000E0
 1 109
23 PF00010 HLH Pfam 4.111E-2 4.363E-2
1.682E-1
1.000E0
 1 112
24 SM00353 HLH SMART 4.291E-2 4.363E-2
1.682E-1
1.000E0
 1 117
25 PS50888 BHLH PROSITE 4.327E-2 4.363E-2
1.682E-1
1.000E0
 1 118
26 IPR011598 bHLH dom InterPro 4.363E-2 4.363E-2
1.682E-1
1.000E0
 1 119
Show 21 more annotations

7: Pathway [Display Chart] 7 input genes in category / 11 annotations before applied cutoff / 12450 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 1270060 Synthesis of PC BioSystems: REACTOME 1.017E-4 1.119E-3 3.379E-3 1.119E-3 2 28
2 1270054 Glycerophospholipid biosynthesis BioSystems: REACTOME 2.196E-3 9.983E-3 3.015E-2 2.415E-2 2 130
3 1269508 Rho GTPase cycle BioSystems: REACTOME 2.723E-3 9.983E-3 3.015E-2 2.995E-2 2 145
4 1270053 Phospholipid metabolism BioSystems: REACTOME 5.520E-3 1.234E-2 3.727E-2
6.072E-2
 2 208
5 1270047 Pregnenolone biosynthesis BioSystems: REACTOME 5.610E-3 1.234E-2 3.727E-2
6.171E-2
 1 10
6 1270045 Recycling of bile acids and salts BioSystems: REACTOME 8.964E-3 1.643E-2 4.963E-2
9.860E-2
 1 16
7 1270046 Metabolism of steroid hormones BioSystems: REACTOME 1.786E-2 2.806E-2
8.475E-2
1.964E-1
 1 32
8 1269507 Signaling by Rho GTPases BioSystems: REACTOME 2.227E-2 2.814E-2
8.499E-2
2.450E-1
 2 430
9 1270040 Bile acid and bile salt metabolism BioSystems: REACTOME 2.393E-2 2.814E-2
8.499E-2
2.633E-1
 1 43
10 138070 Regulation of RhoA activity BioSystems: Pathway Interaction Database 2.558E-2 2.814E-2
8.499E-2
2.814E-1
 1 46
Show 5 more annotations

8: Pubmed [Display Chart] 7 input genes in category / 442 annotations before applied cutoff / 38193 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 15760897 Differential gene regulation of StarD4 and StarD5 cholesterol transfer proteins. Activation of StarD4 by sterol regulatory element-binding protein-2 and StarD5 by endoplasmic reticulum stress. Pubmed 2.879E-8 9.544E-6 6.366E-5 1.273E-5 2 2
2 18403318 Intracellular cholesterol transporter StarD4 binds free cholesterol and increases cholesteryl ester formation. Pubmed 8.637E-8 9.544E-6 6.366E-5 3.818E-5 2 3
3 24440759 The StarD4 subfamily of steroidogenic acute regulatory-related lipid transfer (START) domain proteins: new players in cholesterol metabolism. Pubmed 8.637E-8 9.544E-6 6.366E-5 3.818E-5 2 3
4 20600027 Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. Pubmed 8.637E-8 9.544E-6 6.366E-5 3.818E-5 2 3
5 12011452 The cholesterol-regulated StarD4 gene encodes a StAR-related lipid transfer protein with two closely related homologues, StarD5 and StarD6. Pubmed 1.727E-7 1.527E-5 1.018E-4 7.635E-5 2 4
6 12011453 Crystal structure of the Mus musculus cholesterol-regulated START protein 4 (StarD4) containing a StAR-related lipid transfer domain. Pubmed 4.318E-7 3.181E-5 2.121E-4 1.908E-4 2 6
7 24652767 Histopathology reveals correlative and unique phenotypes in a high-throughput mouse phenotyping screen. Pubmed 2.969E-5 5.587E-4 3.726E-3 1.312E-2 2 46
8 16783635 Quantitative trait loci for body size components in mice. Pubmed 1.248E-4 5.587E-4 3.726E-3
5.518E-2
 2 94
9 16862168 The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
10 20634475 p122 protein enhances intracellular calcium increase to acetylcholine: its possible role in the pathogenesis of coronary spastic angina. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
11 17888903 Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
12 14661059 DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
13 24557030 DLC1 expression is reduced in human cutaneous melanoma and correlates with patient survival. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
14 24604602 Tumor suppressor DLC-1 induces apoptosis and inhibits the growth and invasion of colon cancer cells through the Wnt/β-catenin signaling pathway. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
15 28209730 Role of STARD4 in sterol transport between the endocytic recycling compartment and the plasma membrane. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
16 10649492 Sequence variants of DLC1 in colorectal and ovarian tumours. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
17 16533763 Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
18 9605766 Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
19 16534142 Localization of StarD5 cholesterol binding protein. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
20 26846339 DLC-1 is an independent prognostic marker and potential therapeutic target in hepatocellular cancer. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
21 12770731 START domain proteins and the intracellular trafficking of cholesterol in steroidogenic cells. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
22 18981889 Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
23 20198346 Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
24 22201613 Overexpression of TWIST2 correlates with poor prognosis in head and neck squamous cell carcinomas. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
25 14633684 Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
26 25608809 Biological function and molecular mechanism of Twist2. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
27 20025523 Enhanced generation of myeloid lineages in hematopoietic differentiation from embryonic stem cells by silencing transcriptional repressor Twist-2. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
28 23162637 Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
29 26514520 Clinicopathological Significance of DLC-1 Expression in Cancer: a Meta-Analysis. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
30 25980009 Haploinsufficiency for Stard7 is associated with enhanced allergic responses in lung and skin. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
31 17292327 DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
32 19766077 Association of DLC1 gene polymorphism with susceptibility to hepatocellular carcinoma in Chinese hepatitis B virus carriers. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
33 23033213 STARD4 knockdown in HepG2 cells disrupts cholesterol trafficking associated with the plasma membrane, ER, and ERC. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
34 23511482 PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
35 22002576 Loss of DLC1 is an independent prognostic factor in patients with oral squamous cell carcinoma. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
36 12545165 DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
37 24329682 Inhibitory effects of deleted in liver cancer 1 gene on gallbladder cancer growth through induction of cell cycle arrest and apoptosis. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
38 15809452 TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
39 21217778 A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
40 20059974 StarD4-mediated translocation of 7-hydroperoxycholesterol to isolated mitochondria: deleterious effects and implications for steroidogenesis under oxidative stress conditions. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
41 25728400 Chromosome 1p36.22p36.21 duplications/triplication causes Setleis syndrome (focal facial dermal dysplasia type III). Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
42 14576202 Transcriptional profiling of the heart reveals chamber-specific gene expression patterns. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
43 15201975 Less frequent promoter hypermethylation of DLC-1 gene in primary breast cancers. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
44 18615730 Development of a gene-trap vector with a highly sensitive fluorescent protein reporter system for expression profiling. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
45 26119818 Recurrent Mutations in the Basic Domain of TWIST2 Cause Ablepharon Macrostomia and Barber-Say Syndromes. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
46 12813468 Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
47 23908159 Promoter hypermethylation along with LOH, but not mutation, contributes to inactivation of DLC-1 in nasopharyngeal carcinoma. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
48 21455586 Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
49 24338004 GAP-independent functions of DLC1 in metastasis. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
50 26239822 Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer. Pubmed 1.833E-4 5.587E-4 3.726E-3
8.101E-2
 1 1
Show 45 more annotations

9: Interaction [Display Chart] 5 input genes in category / 92 annotations before applied cutoff / 17703 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 int:STARD10 STARD10 interactions 1.694E-3 2.993E-2
1.528E-1
1.558E-1
 1 6
2 int:GLTP GLTP interactions 1.976E-3 2.993E-2
1.528E-1
1.818E-1
 1 7
3 int:PRELID1 PRELID1 interactions 2.822E-3 2.993E-2
1.528E-1
2.596E-1
 1 10
4 int:TWIST2 TWIST2 interactions 2.822E-3 2.993E-2
1.528E-1
2.596E-1
 1 10
5 int:AGFG2 AGFG2 interactions 2.822E-3 2.993E-2
1.528E-1
2.596E-1
 1 10
6 int:WWC3 WWC3 interactions 2.822E-3 2.993E-2
1.528E-1
2.596E-1
 1 10
7 int:ADGRB2 ADGRB2 interactions 3.103E-3 2.993E-2
1.528E-1
2.855E-1
 1 11
8 int:DOHH DOHH interactions 3.385E-3 2.993E-2
1.528E-1
3.114E-1
 1 12
9 int:CCDC91 CCDC91 interactions 3.667E-3 2.993E-2
1.528E-1
3.373E-1
 1 13
10 int:PHYHIPL PHYHIPL interactions 3.948E-3 2.993E-2
1.528E-1
3.632E-1
 1 14
11 int:PIGM PIGM interactions 4.230E-3 2.993E-2
1.528E-1
3.891E-1
 1 15
12 int:WWC2 WWC2 interactions 4.230E-3 2.993E-2
1.528E-1
3.891E-1
 1 15
13 int:C17orf75 C17orf75 interactions 4.230E-3 2.993E-2
1.528E-1
3.891E-1
 1 15
14 int:CCM2 CCM2 interactions 4.793E-3 3.150E-2
1.608E-1
4.409E-1
 1 17
15 int:DLC1 DLC1 interactions 5.637E-3 3.457E-2
1.765E-1
5.186E-1
 1 20
16 int:NAT2 NAT2 interactions 6.199E-3 3.564E-2
1.819E-1
5.703E-1
 1 22
17 int:STARD7 STARD7 interactions 6.761E-3 3.659E-2
1.868E-1
6.220E-1
 1 24
18 int:KHDC4 KHDC4 interactions 7.323E-3 3.743E-2
1.910E-1
6.737E-1
 1 26
19 int:OPA3 OPA3 interactions 9.006E-3 4.063E-2
2.074E-1
8.286E-1
 1 32
20 int:HMGCR HMGCR interactions 1.013E-2 4.063E-2
2.074E-1
9.317E-1
 1 36
21 int:NDUFAF5 NDUFAF5 interactions 1.013E-2 4.063E-2
2.074E-1
9.317E-1
 1 36
22 int:RCC1L RCC1L interactions 1.013E-2 4.063E-2
2.074E-1
9.317E-1
 1 36
23 int:LACC1 LACC1 interactions 1.069E-2 4.063E-2
2.074E-1
9.833E-1
 1 38
24 int:NDUFAF8 NDUFAF8 interactions 1.097E-2 4.063E-2
2.074E-1
1.000E0
 1 39
25 int:ETS2 ETS2 interactions 1.125E-2 4.063E-2
2.074E-1
1.000E0
 1 40
26 int:STARD13 STARD13 interactions 1.181E-2 4.063E-2
2.074E-1
1.000E0
 1 42
27 int:MEF2C MEF2C interactions 1.209E-2 4.063E-2
2.074E-1
1.000E0
 1 43
28 int:FBXW5 FBXW5 interactions 1.237E-2 4.063E-2
2.074E-1
1.000E0
 1 44
29 int:APOOL APOOL interactions 1.349E-2 4.149E-2
2.118E-1
1.000E0
 1 48
30 int:TWIST1 TWIST1 interactions 1.404E-2 4.149E-2
2.118E-1
1.000E0
 1 50
31 int:S100A10 S100A10 interactions 1.488E-2 4.149E-2
2.118E-1
1.000E0
 1 53
32 int:FEM1B FEM1B interactions 1.488E-2 4.149E-2
2.118E-1
1.000E0
 1 53
33 int:SMARCD3 SMARCD3 interactions 1.488E-2 4.149E-2
2.118E-1
1.000E0
 1 53
34 int:S100A7 S100A7 interactions 1.544E-2 4.160E-2
2.123E-1
1.000E0
 1 55
35 int:SERPINB4 SERPINB4 interactions 1.628E-2 4.160E-2
2.123E-1
1.000E0
 1 58
36 int:INPP5E INPP5E interactions 1.655E-2 4.160E-2
2.123E-1
1.000E0
 1 59
37 int:ITPR1 ITPR1 interactions 1.683E-2 4.160E-2
2.123E-1
1.000E0
 1 60
38 int:WWC1 WWC1 interactions 1.795E-2 4.160E-2
2.123E-1
1.000E0
 1 64
39 int:PLCG2 PLCG2 interactions 1.823E-2 4.160E-2
2.123E-1
1.000E0
 1 65
40 int:EPB41L1 EPB41L1 interactions 1.850E-2 4.160E-2
2.123E-1
1.000E0
 1 66
41 int:DENND4C DENND4C interactions 1.934E-2 4.160E-2
2.123E-1
1.000E0
 1 69
42 int:CHCHD10 CHCHD10 interactions 1.962E-2 4.160E-2
2.123E-1
1.000E0
 1 70
43 int:SREBF1 SREBF1 interactions 1.962E-2 4.160E-2
2.123E-1
1.000E0
 1 70
44 int:TESK2 TESK2 interactions 1.990E-2 4.160E-2
2.123E-1
1.000E0
 1 71
45 int:KIF1B KIF1B interactions 2.045E-2 4.181E-2
2.134E-1
1.000E0
 1 73
46 int:DENND1A DENND1A interactions 2.239E-2 4.361E-2
2.226E-1
1.000E0
 1 80
47 int:RTKN RTKN interactions 2.295E-2 4.361E-2
2.226E-1
1.000E0
 1 82
48 int:TAX1BP1 TAX1BP1 interactions 2.323E-2 4.361E-2
2.226E-1
1.000E0
 1 83
49 int:TLE3 TLE3 interactions 2.350E-2 4.361E-2
2.226E-1
1.000E0
 1 84
50 int:DCLK1 DCLK1 interactions 2.378E-2 4.361E-2
2.226E-1
1.000E0
 1 85
Show 45 more annotations

10: Cytoband [Display Chart] 7 input genes in category / 7 annotations before applied cutoff / 34661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 13q12-q13 13q12-q13 8.076E-4 5.653E-3 1.466E-2 5.653E-3 1 4
2 5q22.1 5q22.1 2.220E-3 7.530E-3 1.952E-2 1.554E-2 1 11
3 15q26 15q26 3.227E-3 7.530E-3 1.952E-2 2.259E-2 1 16
4 8p22 8p22 8.252E-3 1.444E-2 3.744E-2
5.776E-2
 1 41
5 2q11.2 2q11.2 1.485E-2 2.035E-2
5.276E-2
1.040E-1
 1 74
6 2q37.3 2q37.3 1.744E-2 2.035E-2
5.276E-2
1.221E-1
 1 87
7 11q13 11q13 2.379E-2 2.379E-2
6.168E-2
1.665E-1
 1 119
Show 2 more annotations

11: Transcription Factor Binding Site [Display Chart] 7 input genes in category / 74 annotations before applied cutoff / 9770 genes in category

No results to display

12: Gene Family [Display Chart] 7 input genes in category / 3 annotations before applied cutoff / 18194 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 759 StAR related lipid transfer domain containing genenames.org 6.957E-19 2.087E-18 3.827E-18 2.087E-18 6 15
2 721 Rho GTPase activating proteins genenames.org 1.541E-4 2.311E-4 4.237E-4 4.622E-4 2 50
3 420 Basic helix-loop-helix proteins genenames.org 4.157E-2 4.157E-2
7.621E-2
1.247E-1
 1 110

13: Coexpression [Display Chart] 7 input genes in category / 787 annotations before applied cutoff / 23137 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 M8053 Genes up-regulated in macrophages: wildtype versus PPARG [GeneID=5468] knockout. MSigDB C7: Immunologic Signatures (v6.0) 2.171E-5 1.708E-2
1.238E-1
 1.708E-2 3 200
2 19286929-SuppTable2r Mouse Lung Rangasamy09 67genes GeneSigDB 1.377E-4 4.118E-2
2.984E-1
1.084E-1
 2 60
3 20713713-TableS1b Human Breast Taube10 91genes EMTsignature up GeneSigDB 2.703E-4 4.118E-2
2.984E-1
2.127E-1
 2 84
4 19962670-TableS2 Human Ovarian Mok09 200Genes GeneSigDB 7.065E-4 4.118E-2
2.984E-1
5.560E-1
 2 136
5 17161497-SuppTable1 Human Lung Dracheva07 162genes GeneSigDB 8.134E-4 4.118E-2
2.984E-1
6.402E-1
 2 146
6 M10605 Genes down-regulated in medullary breast cancer (MBC) relative to ductal breast cancer (DBD). MSigDB C2: CGP Curated Gene Sets (v6.0) 1.087E-3 4.118E-2
2.984E-1
8.557E-1
 2 169
7 M8990 Genes up-regulated in CD4 [GeneID=920] T cells treated with rosiglitazone [PubChem=77999] and over-expressing: FOXP3 [GeneID=50943] and PPARg1 isoform of PPARG [GeneID=5468] versus FOXP3 [GeneID=50943] and PPARg2 isoform of PPARG [GeneID=5468]. MSigDB C7: Immunologic Signatures (v6.0) 1.152E-3 4.118E-2
2.984E-1
9.066E-1
 2 174
8 15588851-Table3 Human Breast Gatalica05 4genes GeneSigDB 1.210E-3 4.118E-2
2.984E-1
9.520E-1
 1 4
9 M7406 Genes down-regulated in immature neuron cell line: control versus interferon alpha (12h). MSigDB C7: Immunologic Signatures (v6.0) 1.371E-3 4.118E-2
2.984E-1
1.000E0
 2 190
10 M8371 Genes up-regulated in CD4 [GeneID=920] T cells: untreated versus TGFB1 [GeneID=7040]. MSigDB C7: Immunologic Signatures (v6.0) 1.502E-3 4.118E-2
2.984E-1
1.000E0
 2 199
11 M4221 Genes up-regulated in comparison of CD4 [GeneID=920] T cells treated with IL4 [GeneID=3565] and anti-IL12 at 12 h versus the untreated cells at 12 h. MSigDB C7: Immunologic Signatures (v6.0) 1.502E-3 4.118E-2
2.984E-1
1.000E0
 2 199
12 M9701 Genes down-regulated in macrophage differentiated by: CSF1 [GeneID=1435] versus CSF1 [GeneID=1435] and IL27 [GeneID=246778]. MSigDB C7: Immunologic Signatures (v6.0) 1.502E-3 4.118E-2
2.984E-1
1.000E0
 2 199
13 M4867 Genes down-regulated in comparison of NKT cells versus erythroblasts. MSigDB C7: Immunologic Signatures (v6.0) 1.502E-3 4.118E-2
2.984E-1
1.000E0
 2 199
14 M3926 Genes down-regulated in comparison of dendritic cells (DC) stimulated with LPS (TLR4 agonist) at 12 h versus DC cells stimulated with Pam3Csk4 (TLR1/2 agonist) at 12 h. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
15 M4565 Genes up-regulated in adult DN2 thymocytes versus adult DN3 thymocytes. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
16 M8465 Genes down-regulated in activated CD4 [GeneID=920] T cells: wildtype versus over-expressing MIR17 [GeneID=406952]. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
17 M3760 Genes down-regulated in comparison of control dendritic cells (DC) at 2 h versus those stimulated with CpG DNA (TLR9 agonist) at 2 h. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
18 M9553 Genes up-regulated in KLRG1 low [GeneID=10219] CD8 T effector cells during infection: wildtype versus ID2 [GeneID=3398]. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
19 M9699 Genes up-regulated in immature dendritic cells: untreated versus IL27 [GeneID=246778]. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
20 M6621 Genes down-regulated in bone marrow-derived macrophages with IL6 [GeneID=3569] knockout and 45 min of stimulation by: LPS versus IL6 [GeneID=3569] and LPS. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
21 M5533 Genes down-regulated in comparison of neutrophils versus Th1 cells. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
22 M6030 Genes down-regulated in CD4 [GeneID=920] T cells activated by anti-CD3 and anti-CD28: IL-12 (48h) versus IL4 [GeneID=3565] (48h). MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
23 M7147 Genes up-regulated in CD8A- [GeneID=925] splenic dendritic cells: wildtype versus IFNAR1 [GeneID=3454] knockout mice. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
24 M4252 Genes down-regualted in comparison of regulatory T cell (Treg) from CBFB [GeneID=865] deficient mice versus those from wild type animals. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
25 M3571 Genes down-regulated in comparison of wild type CD8 effector T cells at day 6 versus those from mice defficient for TRAF6 [GeneID=7189] at day 6. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
26 M8384 Genes down-regulated in CD4 [GeneID=920] T cells: untreated versus progesterone [PubChem=5994]. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
27 M3350 Genes down-regulated in comparison of dendritic cells (DC) before and 16 h after LPS (TLR4 agonist) stimulation. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
28 M4066 Genes down-regulated in comparison of dendritic cells (DC) stimulated with LPS (TLR4 agonist) at 24 h versus DC cells stimulated with Gardiquimod (TLR7 agonist) at 24 h. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
29 M8846 Genes down-regulated in NK cells: RAG2 [GeneID=5897] knockout versus RAG2 and ETS1 [GeneID=5897;2113] knockout. MSigDB C7: Immunologic Signatures (v6.0) 1.517E-3 4.118E-2
2.984E-1
1.000E0
 2 200
Show 24 more annotations

14: Coexpression Atlas [Display Chart] 7 input genes in category / 552 annotations before applied cutoff / 21829 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 Kidney10XCellRanger Six2TGC TSC1 P0 Stroma Stroma Subtype P0-Six2TGC Tsc1-Stroma3-C4-KC2 Top 200 Genes Kidney10XCellRanger Six2TGC TSC1 P0 Stroma Stroma Subtype P0-Six2TGC Tsc1-Stroma3-C4-KC2 Top 200 Genes 6.176E-5 2.336E-2
1.610E-1
 3.409E-2 3 268
2 gudmap dev gonad e12.5 M gudmap devVasTestis Flk k2 500 dev gonad e12.5 M DevVasTestis Flk k-means-cluster#2 top-relative-expression-ranked 500 Gudmap Mouse ST 1.0 8.465E-5 2.336E-2
1.610E-1
 4.672E-2 3 298
3 gudmap dev gonad e12.5 M gudmap devVasTestis Flk 500 dev gonad e12.5 M DevVasTestis Flk top-relative-expression-ranked 500 Gudmap Mouse ST 1.0 2.240E-4 3.799E-2
2.618E-1
1.236E-1
 3 414
4 gudmap dev gonad e11.5 F ReproVasc Flk k3 1000 dev gonad e11.5 F ReproVasc Flk k-means-cluster#3 top-relative-expression-ranked 1000 Gudmap Mouse ST 1.0 2.753E-4 3.799E-2
2.618E-1
1.519E-1
 3 444
5 Sample Type by Project: Shred 1/TCGA-Adrenal Cortex/Adrenocortical carcinoma/Usual Type/4/1 Sample Type by Project: Shred 1/TCGA-Adrenal Cortex/Adrenocortical carcinoma/Usual Type/4/1 TCGA-Adrenal Cortex 3.719E-4 4.106E-2
2.829E-1
2.053E-1
 2 93

15: Computational [Display Chart] 7 input genes in category / 88 annotations before applied cutoff / 10037 genes in category

No results to display

16: MicroRNA [Display Chart] 7 input genes in category / 285 annotations before applied cutoff / 72241 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 hsa-miR-3074-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.373E-5 5.520E-3 3.440E-2 1.246E-2 2 105
2 hsa-miR-7152-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.715E-5 5.520E-3 3.440E-2 1.629E-2 2 120
3 hsa-miR-4452:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.811E-5 5.520E-3 3.440E-2 1.656E-2 2 121
4 hsa-miR-578:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 8.932E-5 6.364E-3 3.966E-2 2.546E-2 2 150
5 ATACCTC,MIR-202:MSigDB ATACCTC,MIR-202:MSigDB MSigDB 1.147E-4 6.539E-3 4.075E-2 3.269E-2 2 170
6 hsa-miR-202:PITA hsa-miR-202:PITA TOP PITA 1.954E-4 9.283E-3
5.785E-2
5.570E-2
 2 222
7 hsa-miR-1236:PITA hsa-miR-1236:PITA TOP PITA 2.283E-4 9.295E-3
5.792E-2
6.506E-2
 2 240
8 hsa-miR-6767-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.844E-4 1.186E-2
7.391E-2
1.381E-1
 1 5
9 hsa-miR-4283:mirSVR highEffct hsa-miR-4283:mirSVR nonconserved highEffect-0.5 MicroRNA.org 4.892E-4 1.186E-2
7.391E-2
1.394E-1
 2 352
10 hsa-miR-3666:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.229E-4 1.186E-2
7.391E-2
1.490E-1
 2 364
11 hsa-miR-4295:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.286E-4 1.186E-2
7.391E-2
1.507E-1
 2 366
12 hsa-miR-301b-3p:Non-Functional MTI Non-Functional MTI miRTarbase 5.547E-4 1.186E-2
7.391E-2
1.581E-1
 2 375
13 hsa-miR-301a-3p:Functional MTI Functional MTI miRTarbase 6.150E-4 1.186E-2
7.391E-2
1.753E-1
 2 395
14 hsa-miR-454-3p:Functional MTI Functional MTI miRTarbase 6.181E-4 1.186E-2
7.391E-2
1.762E-1
 2 396
15 hsa-miR-130a-3p:Functional MTI Functional MTI miRTarbase 6.243E-4 1.186E-2
7.391E-2
1.779E-1
 2 398
16 hsa-miR-638:PITA hsa-miR-638:PITA TOP PITA 1.162E-3 2.070E-2
1.290E-1
3.312E-1
 1 12
17 hsa-miR-24-2-5p:Functional MTI Functional MTI miRTarbase 3.097E-3 3.227E-2
2.011E-1
8.826E-1
 1 32
18 hsa-miR-1258:Functional MTI Functional MTI miRTarbase 3.483E-3 3.227E-2
2.011E-1
9.927E-1
 1 36
19 hsa-miR-24-1-5p:Functional MTI Functional MTI miRTarbase 3.483E-3 3.227E-2
2.011E-1
9.927E-1
 1 36
20 hsa-miR-6766-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.676E-3 3.227E-2
2.011E-1
1.000E0
 1 38
21 hsa-miR-4782-3p:Functional MTI Functional MTI miRTarbase 3.966E-3 3.227E-2
2.011E-1
1.000E0
 1 41
22 hsa-miR-1231:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.352E-3 3.227E-2
2.011E-1
1.000E0
 1 45
23 hsa-miR-219a-5p:Functional MTI Functional MTI miRTarbase 4.449E-3 3.227E-2
2.011E-1
1.000E0
 1 46
24 hsa-miR-3682-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.546E-3 3.227E-2
2.011E-1
1.000E0
 1 47
25 GGGATGC,MIR-324-5P:MSigDB GGGATGC,MIR-324-5P:MSigDB MSigDB 4.739E-3 3.227E-2
2.011E-1
1.000E0
 1 49
26 hsa-miR-4445-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.835E-3 3.227E-2
2.011E-1
1.000E0
 1 50
27 hsa-miR-660-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.835E-3 3.227E-2
2.011E-1
1.000E0
 1 50
28 hsa-miR-3140-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.028E-3 3.227E-2
2.011E-1
1.000E0
 1 52
29 hsa-miR-638:Functional MTI Functional MTI miRTarbase 5.125E-3 3.227E-2
2.011E-1
1.000E0
 1 53
30 hsa-miR-4774-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.221E-3 3.227E-2
2.011E-1
1.000E0
 1 54
31 GTAAGAT,MIR-200A:MSigDB GTAAGAT,MIR-200A:MSigDB MSigDB 5.221E-3 3.227E-2
2.011E-1
1.000E0
 1 54
32 hsa-miR-6740-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.317E-3 3.227E-2
2.011E-1
1.000E0
 1 55
33 hsa-miR-3137:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.317E-3 3.227E-2
2.011E-1
1.000E0
 1 55
34 GGTGAAG,MIR-412:MSigDB GGTGAAG,MIR-412:MSigDB MSigDB 5.414E-3 3.227E-2
2.011E-1
1.000E0
 1 56
35 hsa-miR-491-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.607E-3 3.227E-2
2.011E-1
1.000E0
 1 58
36 hsa-miR-508-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.703E-3 3.227E-2
2.011E-1
1.000E0
 1 59
37 hsa-miR-4258:mirSVR highEffct hsa-miR-4258:mirSVR nonconserved highEffect-0.5 MicroRNA.org 5.992E-3 3.227E-2
2.011E-1
1.000E0
 1 62
38 hsa-miR-4502:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.992E-3 3.227E-2
2.011E-1
1.000E0
 1 62
39 hsa-miR-8065:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.185E-3 3.227E-2
2.011E-1
1.000E0
 1 64
40 hsa-miR-4450:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.282E-3 3.227E-2
2.011E-1
1.000E0
 1 65
41 hsa-miR-4507:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.378E-3 3.227E-2
2.011E-1
1.000E0
 1 66
42 hsa-miR-4653-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.474E-3 3.227E-2
2.011E-1
1.000E0
 1 67
43 hsa-miR-3591-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.571E-3 3.227E-2
2.011E-1
1.000E0
 1 68
44 hsa-miR-4749-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.571E-3 3.227E-2
2.011E-1
1.000E0
 1 68
45 hsa-miR-3940-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.571E-3 3.227E-2
2.011E-1
1.000E0
 1 68
46 hsa-miR-513b-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.667E-3 3.227E-2
2.011E-1
1.000E0
 1 69
47 hsa-miR-219a-1-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.667E-3 3.227E-2
2.011E-1
1.000E0
 1 69
48 hsa-miR-6839-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.667E-3 3.227E-2
2.011E-1
1.000E0
 1 69
49 hsa-miR-501-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.667E-3 3.227E-2
2.011E-1
1.000E0
 1 69
50 hsa-miR-6882-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.667E-3 3.227E-2
2.011E-1
1.000E0
 1 69
Show 45 more annotations

17: Drug [Display Chart] 7 input genes in category / 1405 annotations before applied cutoff / 22841 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 CID000065094 25-hydroxycholesterol Stitch 1.157E-5 1.275E-2
9.981E-2
 1.625E-2 3 160
2 839 DN 5224221; Down 200; 12uM; MCF7; HT HG-U133A EA Broad Institute CMAP Down 1.816E-5 1.275E-2
9.981E-2
 2.551E-2 3 186
3 ctd:C002994 ethylene dimethanesulfonate CTD 1.101E-4 4.288E-2
3.355E-1
1.547E-1
 2 53
4 CID000000405 7 alpha-hydroxycholesterol Stitch 1.413E-4 4.288E-2
3.355E-1
1.985E-1
 2 60
5 7105 UP trichostatin A, Streptomyces sp.; Up 200; 1uM; PC3; HT HG-U133A Broad Institute CMAP Up 1.168E-3 4.288E-2
3.355E-1
1.000E0
 2 173
6 956 DN 5224221; Down 200; 12uM; MCF7; HT HG-U133A EA Broad Institute CMAP Down 1.264E-3 4.288E-2
3.355E-1
1.000E0
 2 180
7 5640 DN Digoxigenin [1672-46-4]; Down 200; 10.2uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.264E-3 4.288E-2
3.355E-1
1.000E0
 2 180
8 3275 DN Digitoxigenin [143-62-4]; Down 200; 10.6uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.278E-3 4.288E-2
3.355E-1
1.000E0
 2 181
9 6048 DN Lanatoside C [17575-22-3]; Down 200; 4uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.278E-3 4.288E-2
3.355E-1
1.000E0
 2 181
10 6087 DN Strophanthidin [66-28-4]; Down 200; 9.8uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.306E-3 4.288E-2
3.355E-1
1.000E0
 2 183
11 3963 DN Lanatoside C [17575-22-3]; Down 200; 4uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.320E-3 4.288E-2
3.355E-1
1.000E0
 2 184
12 2532 UP Alclometasone dipropionate [667634-13-2]; Up 200; 7.6uM; HL60; HT HG-U133A Broad Institute CMAP Up 1.334E-3 4.288E-2
3.355E-1
1.000E0
 2 185
13 4835 DN Nifuroxazide [965-52-6]; Down 200; 14.6uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.377E-3 4.288E-2
3.355E-1
1.000E0
 2 188
14 2375 UP Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT HG-U133A Broad Institute CMAP Up 1.406E-3 4.288E-2
3.355E-1
1.000E0
 2 190
15 7045 DN lomustine; Down 200; 100uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.421E-3 4.288E-2
3.355E-1
1.000E0
 2 191
16 6990 DN 15d-PGJ2; Down 200; 10uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.436E-3 4.288E-2
3.355E-1
1.000E0
 2 192
17 6574 DN 5155877; Down 200; 10uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.451E-3 4.288E-2
3.355E-1
1.000E0
 2 193
18 4424 DN Tadjakonine [11087-94-8]; Down 200; 7.4uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.465E-3 4.288E-2
3.355E-1
1.000E0
 2 194
19 7089 DN lomustine; Down 200; 100uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.465E-3 4.288E-2
3.355E-1
1.000E0
 2 194
20 3282 UP Chlorogenic acid [327-97-9]; Up 200; 11.2uM; MCF7; HT HG-U133A Broad Institute CMAP Up 1.480E-3 4.288E-2
3.355E-1
1.000E0
 2 195
21 5228 DN 15d-PGJ2; Down 200; 10uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.495E-3 4.288E-2
3.355E-1
1.000E0
 2 196
22 2710 DN Levonordefrin [829-74-3]; Down 200; 21.8uM; HL60; HT HG-U133A Broad Institute CMAP Down 1.495E-3 4.288E-2
3.355E-1
1.000E0
 2 196
23 2837 UP Propylthiouracil [51-52-5]; Up 200; 23.4uM; MCF7; HT HG-U133A Broad Institute CMAP Up 1.495E-3 4.288E-2
3.355E-1
1.000E0
 2 196
24 3049 DN Pentetic acid [67-43-6]; Down 200; 10.2uM; HL60; HT HG-U133A Broad Institute CMAP Down 1.495E-3 4.288E-2
3.355E-1
1.000E0
 2 196
25 2447 UP Ceforanide [60925-61-3]; Up 200; 7.6uM; HL60; HT HG-U133A Broad Institute CMAP Up 1.495E-3 4.288E-2
3.355E-1
1.000E0
 2 196
26 5321 UP Nitrofural [59-87-0]; Up 200; 20.2uM; MCF7; HT HG-U133A Broad Institute CMAP Up 1.511E-3 4.288E-2
3.355E-1
1.000E0
 2 197
27 6167 DN Rapamycin; Down 200; 0.1uM; HL60; HT HG-U133A Broad Institute CMAP Down 1.511E-3 4.288E-2
3.355E-1
1.000E0
 2 197
28 2994 DN Methylhydantoin-5-(D) [55147-68-7]; Down 200; 35uM; HL60; HT HG-U133A Broad Institute CMAP Down 1.511E-3 4.288E-2
3.355E-1
1.000E0
 2 197
29 2533 UP (R) -Naproxen sodium salt [26159-34-2]; Up 200; 15.8uM; HL60; HT HG-U133A Broad Institute CMAP Up 1.511E-3 4.288E-2
3.355E-1
1.000E0
 2 197
30 5357 UP Deoxycorticosterone [64-85-7]; Up 200; 12.2uM; MCF7; HT HG-U133A Broad Institute CMAP Up 1.511E-3 4.288E-2
3.355E-1
1.000E0
 2 197
31 5052 UP Allantoin [97-59-6]; Up 200; 25.2uM; PC3; HT HG-U133A Broad Institute CMAP Up 1.511E-3 4.288E-2
3.355E-1
1.000E0
 2 197
32 4089 DN Amyleine hydrochloride [532-59-2]; Down 200; 14.8uM; PC3; HT HG-U133A Broad Institute CMAP Down 1.511E-3 4.288E-2
3.355E-1
1.000E0
 2 197
33 3069 UP Butylparaben [94-26-8]; Up 200; 20.6uM; HL60; HT HG-U133A Broad Institute CMAP Up 1.511E-3 4.288E-2
3.355E-1
1.000E0
 2 197
34 2516 UP Trioxsalen [3902-71-4]; Up 200; 17.6uM; HL60; HT HG-U133A Broad Institute CMAP Up 1.511E-3 4.288E-2
3.355E-1
1.000E0
 2 197
35 6061 DN Diphenylpyraline hydrochloride [132-18-3]; Down 200; 12.6uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.511E-3 4.288E-2
3.355E-1
1.000E0
 2 197
36 5493 DN Chlorpromazine hydrochloride [69-09-0]; Down 200; 11.2uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.511E-3 4.288E-2
3.355E-1
1.000E0
 2 197
37 4569 DN Novobiocin sodium salt [1476-53-5]; Down 200; 6.4uM; PC3; HT HG-U133A Broad Institute CMAP Down 1.526E-3 4.288E-2
3.355E-1
1.000E0
 2 198
38 4004 DN Boldine [476-70-0]; Down 200; 12.2uM; PC3; HT HG-U133A Broad Institute CMAP Down 1.526E-3 4.288E-2
3.355E-1
1.000E0
 2 198
39 7328 DN Nifurtimox [23256-30-6]; Down 200; 14uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.526E-3 4.288E-2
3.355E-1
1.000E0
 2 198
40 3093 UP Pipemidic acid [51940-44-4]; Up 200; 13.2uM; HL60; HT HG-U133A Broad Institute CMAP Up 1.526E-3 4.288E-2
3.355E-1
1.000E0
 2 198
41 4810 DN Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride; Down 200; 16.4uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.526E-3 4.288E-2
3.355E-1
1.000E0
 2 198
42 6154 UP Thiethylperazine malate [52239-63-1]; Up 200; 6uM; HL60; HT HG-U133A Broad Institute CMAP Up 1.526E-3 4.288E-2
3.355E-1
1.000E0
 2 198
43 7452 DN Trazodone hydrochloride [25332-39-2]; Down 200; 9.8uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.541E-3 4.288E-2
3.355E-1
1.000E0
 2 199
44 2496 UP (R)-(+)-Atenolol [56715-13-0]; Up 200; 15uM; HL60; HT HG-U133A Broad Institute CMAP Up 1.541E-3 4.288E-2
3.355E-1
1.000E0
 2 199
45 5473 DN Ceftazidime pentahydrate [78439-06-2]; Down 200; 6.2uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.541E-3 4.288E-2
3.355E-1
1.000E0
 2 199
46 2731 DN Gabapentin [60142-96-3]; Down 200; 23.4uM; HL60; HT HG-U133A Broad Institute CMAP Down 1.541E-3 4.288E-2
3.355E-1
1.000E0
 2 199
47 5728 UP Tetrahydroalstonine [6474-90-4]; Up 200; 11.4uM; PC3; HT HG-U133A Broad Institute CMAP Up 1.541E-3 4.288E-2
3.355E-1
1.000E0
 2 199
48 3089 UP Bephenium hydroxynaphthoate [3818-50-6]; Up 200; 9uM; HL60; HT HG-U133A Broad Institute CMAP Up 1.541E-3 4.288E-2
3.355E-1
1.000E0
 2 199
49 2677 UP chlorpromazine hydrochloride; Up 200; 1uM; HL60; HT HG-U133A Broad Institute CMAP Up 1.541E-3 4.288E-2
3.355E-1
1.000E0
 2 199
50 3421 UP Ethoxyquin [91-53-2]; Up 200; 18.4uM; MCF7; HT HG-U133A Broad Institute CMAP Up 1.541E-3 4.288E-2
3.355E-1
1.000E0
 2 199
Show 45 more annotations

18: Disease [Display Chart] 5 input genes in category / 49 annotations before applied cutoff / 16205 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 cv:C1744559 Congenital ectodermal dysplasia of face Clinical Variations 3.085E-4 6.047E-3 2.708E-2 1.512E-2 1 1
2 C1744559 Congenital ectodermal dysplasia of face DisGeNET Curated 3.085E-4 6.047E-3 2.708E-2 1.512E-2 1 1
3 C2936827 Focal facial dermal dysplasia DisGeNET BeFree 6.170E-4 6.047E-3 2.708E-2 3.023E-2 1 2
4 C0278785 recurrent adult acute lymphoblastic leukemia DisGeNET BeFree 6.170E-4 6.047E-3 2.708E-2 3.023E-2 1 2
5 C0266574 Ablepharon DisGeNET Curated 6.170E-4 6.047E-3 2.708E-2 3.023E-2 1 2
6 C1319466 Barber Say syndrome DisGeNET Curated 9.254E-4 7.558E-3 3.385E-2 4.535E-2 1 3
7 C0155826 Chronic nasopharyngitis DisGeNET BeFree 1.850E-3 1.295E-2
5.801E-2
9.066E-2
 1 6
8 C0016395 Focal Dermal Hypoplasia DisGeNET Curated 2.158E-3 1.322E-2
5.921E-2
1.058E-1
 1 7
9 C0153690 Secondary malignant neoplasm of bone DisGeNET BeFree 3.691E-3 1.963E-2
8.791E-2
1.809E-1
 2 318
10 C1336538 Supratentorial Primitive Neuroectodermal Tumor DisGeNET BeFree 4.005E-3 1.963E-2
8.791E-2
1.963E-1
 1 13
11 C0206660 Germinoma DisGeNET BeFree 4.928E-3 2.195E-2
9.832E-2
2.415E-1
 1 16
12 C1860224 ABLEPHARON-MACROSTOMIA SYNDROME DisGeNET Curated 5.849E-3 2.212E-2
9.907E-2
2.866E-1
 1 19
13 C0030186 Paget Disease Extramammary DisGeNET BeFree 6.464E-3 2.212E-2
9.907E-2
3.167E-1
 1 21
14 C4020813 Increased gastric cancer DisGeNET Curated 6.464E-3 2.212E-2
9.907E-2
3.167E-1
 1 21
15 C0812437 Oculo-dento-digital syndrome DisGeNET Curated 6.770E-3 2.212E-2
9.907E-2
3.318E-1
 1 22
16 OMIN:114500 COLORECTAL CANCER; CRC OMIM 7.691E-3 2.305E-2
1.033E-1
3.769E-1
 1 25
17 C4024989 Hereditary nonpolyposis colorectal carcinoma DisGeNET Curated 7.997E-3 2.305E-2
1.033E-1
3.919E-1
 1 26
18 C0796070 MICROPHTHALMIA, SYNDROMIC 7 DisGeNET Curated 9.223E-3 2.485E-2
1.113E-1
4.519E-1
 1 30
19 C0280631 Leiomyosarcoma of uterus DisGeNET Curated 1.014E-2 2.485E-2
1.113E-1
4.970E-1
 1 33
20 C0153405 Malignant neoplasm of pharynx DisGeNET BeFree 1.014E-2 2.485E-2
1.113E-1
4.970E-1
 1 33
21 C0021367 Mammary Ductal Carcinoma DisGeNET BeFree 1.533E-2 3.578E-2
1.603E-1
7.514E-1
 1 50
22 C0033300 Progeria DisGeNET Curated 1.747E-2 3.890E-2
1.742E-1
8.558E-1
 1 57
23 C0278678 Metastatic Renal Cell Cancer DisGeNET BeFree 1.868E-2 3.980E-2
1.783E-1
9.154E-1
 1 61
24 C0238339 Hereditary pancreatitis DisGeNET Curated 2.202E-2 4.496E-2
2.014E-1
1.000E0
 1 72
Show 19 more annotations